Ted Hibben

Over the course of his career, Ted has devised and executed on business development and corporate strategy at multiple early-stage biotherapeutic companies as a member of senior leadership. In addition to fundraising roles, he has formed over $3 billion in platform and product R&D collaborations, IPOs, mergers and trade sales with multiple Big Pharma/Biotechs including the $233M sale of the vaccine platform company Coley Pharmaceutical Group to Pfizer. Ted earned his A.B. at Dartmouth College and M.B.A. from Harvard.